BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, June 11, 2026
Home » BioWorld Stock Report For Public Biotechnology Companies

BioWorld Stock Report For Public Biotechnology Companies

June 20, 2005


Article reprints

To read more on related topics, click on one of the words below.

Medical technology
    • Related Articles

      BioWorld Stock Report For Public Biotechnology Companies Part 2

      BioWorld Stock Report For Public Biotechnology Companies

      BioWorld Stock Report For Public Biotechnology Companies

    Popular Stories

    • Today's news in brief

      BioWorld
      BioWorld briefs for June 10, 2026.
    • News in brief

      BioWorld Asia
      BioWorld Asia briefs for June 9, 2026
    • 3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

      Skape Bio unlocks GPCR targets with de novo-designed miniproteins

      BioWorld
      Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
    • Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors

      BioWorld Science
      Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.
    • Wuxi Apptec signage

      Wuxi Apptec insists it’s ‘not a Chinese military company’

      BioWorld
      Wuxi Apptec isn’t going down without a fight after the U.S. Department of Defense added it to the Section 1260H list June 8 as a designated “Chinese military...
    • BioWorld
      • Today's news
      • Analysis and data insight
      • Clinical
      • Data Snapshots
      • Deals and M&A
      • Financings
      • Medical technology
      • Newco news
      • Opinion
      • Regulatory
    • BioWorld Science
      • Today's news
      • Biomarkers
      • Cancer
      • Conferences
      • Endocrine/metabolic
      • Immune
      • Infection
      • Neurology/psychiatric
      • NME Digest
      • Patents
    • BioWorld Asia
      • Today's news
      • Analysis and data insight
      • Australia
      • China
      • Clinical
      • Deals and M&A
      • Financings
      • Newco news
      • Regulatory
      • Science
    • More
      • About
      • Advertise with BioWorld
      • Archives
      • Article reprints and permissions
      • Contact us
      • Cookie policy
      • Copyright notice
      • Data methodology
      • Infographics: Dynamic digital data analysis
      • Index insights
      • Podcasts
      • Privacy policy
      • Share your news with BioWorld
      • Staff
      • Terms of use
      • Topic alerts
    Follow Us

    Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing